The use of onabotulinumtoxinA to treat idiopathic overactive bladder in elderly patients is in need of study.

Manns, Kate; Khan, Asher; Carlson, Kevin V; Wagg, Adrian; Baverstock, Richard J; Trafford Crump, R

Manns, Kate; Khan, Asher; Carlson, Kevin V; Wagg, Adrian; Baverstock, Richard J; Trafford Crump, R.

Afiliação

Manns K; Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Khan A; Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Carlson KV; Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Wagg A; Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.
Baverstock RJ; Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Trafford Crump R; Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.

Neurourol Urodyn ; 41(1): 42-47, 2022 01.

Article em En | MEDLINE | ID: mdl-34618366

Assuntos

Toxinas Botulínicas Tipo A; Bexiga Urinária Hiperativa; Adolescente; Idoso; Toxinas Botulínicas Tipo A/efeitos adversos; Humanos; Pacientes; Resultado do Tratamento; Bexiga Urinária; Bexiga Urinária Hiperativa/terapia

Palavras-chave

age factors; botulinum toxins; overactive; type A; urinary bladder; urology

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Toxinas Botulínicas Tipo A / Bexiga Urinária Hiperativa Tipo de estudo: Clinical_trials / Risk_factors_studies / Systematic_reviews Limite: Adolescent / Aged / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google